A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy

Formulary

Volumn 40, Issue 4, 2005, Pages 114-130

  Dailey, George ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; BIGUANIDE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; HUMULIN U; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COST CONTROL; COUNSELING; DIABETES CONTROL; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; EDEMA; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTESTINE GAS; KIDNEY DISEASE; LACTIC ACIDOSIS; LIFESTYLE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PRACTICE GUIDELINE; RETINOPATHY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; TITRIMETRY; TREATMENT FAILURE; WEIGHT GAIN;

EID: 18244395527     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28:S4-S6.
2. American Diabetes Association. National Diabetes Fact Sheet: General information and national estimates on diabetes in the United States, 2002. Available at: http://www.diabetes.org/diabetes-statistics/national-diabetes- fact-sheet.jsp. Accessed March 14, 2005.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
4. Polonsky KS. Lilly Lecture 1994. The beta-cell in diabetes: from molecular genetics to clinical research. Diabetes. 1995;44:705-717.
5. Hogan P, Dall T, Nikolov P, and the American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-932.
6. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med. 1998;128:517-523.
7. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
8. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389.
9. Nathan DM, Lachin J, Cleary P, et al, and the Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303.
10. Cleary P, Orchard T, Zinman B, and the DCCT/EDIC study group. Coronary calcification in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort [abstract]. Presented at: The 63rd Annual Scientific Sessions of the American Diabetes Association; June 13-17, 2003; New Orleans, La. Abstract 652-P.
11. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
12. Fleming BB, Greenfield S, Engelgau MM, Pogach LM, Clauser SB, Parrott MA. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care. 2001;24:1815-1820.
13. Roy R, Navar M, Palomeno G, Davidson MB. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Diabetes Care. 2004;27:1741-1742.
14. American Association of Clinical Endocrinologists and the American College of Endocrinology. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management-2002 update. Endocr Pract. 2002;8(suppl 1):40-82
15. Buse JB. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. Diabetes Care. 1999;22 Suppl 3:C65-C70.
16. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. Management of Type 2 Diabetes: a Systematic Approach to Meeting the Standards of Care. II: Oral Agents, Insulin, and Management of Complications. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia, Pa: W.B. Saunders Co: 2001:821-835.
17. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, and the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
18. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8:271-275.
19. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004.
20. Actos [package insert]. Lincolnshire, IL: Takeda Pharmaceuticals America; 2004.
21. Glucophage/Glucophage XR [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2004.
22. Glucotrol XL [prescribing information]. New York, NY: Pfizer, Inc.; 2003.
23. Precose [prescribing information]. West Haven, CT: Bayer Pharmaceuticals Corporation; 2004.
24. Glyset [prescribing information]. New York, NY: Pharmacia & Upjohn Company; 2004.
25. Gryskiewicz KA, Coleman CI. Focus on exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes. Formulary. 2005;40:86-90.
26. Defronzo R, Ratner R, Han J, Kim D, Fineman M, Baron AD. Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [abstract]. Presented at: The 64th Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, Fla. Abstract 6.
27. Buse JB, Henry RR, Han J, et al, and the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
28. Kendall DM, Riddle MC, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea [abstract]. Presented at The 64th Annual Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, Fla. Abstract 10.
29. Turner RC, Cull CA, Frighi V, Holman RR, and the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
30. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885.
31. Rohlfing CL, Wiedmeyer HM, Little RR, England JG, Tennil A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275-278.
32. Optimizing insulin therapy in type 2 diabetes. Proceedings from: Optimizing Control: Redefining Intensive Management of Type 2 Diabetes Mellitus roundtable; July 12-13, 2003; New York, NY.
33. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3598-3604.
34. Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004;116:223-229.
35. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:737-745.
36. Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm. 2003;9:309-316.
37. 2004 Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Medical Economics; 2004.
38. Kabadi UM. Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents. Managed Care. 2004;13:48-49, 53-56, 58-59.
39. Riddle MC, Rosenstock J, Gerich J, and the Insuline Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
40. Raskin P, Allen E, Hollander P, et al, and the INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
41. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
42. Fritsche A, Schweitzer MA, Häring HU, and the 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138:952-959.
43. Fritsche A, Schmülling RM, Häring HU, Stumvoll M. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol. 2000;37:13-18.
44. Ponssen HH, Elte JWF, Lehert P, Schouten JP, Bets D. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Clin Ther. 2000;22:709-718.
45. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20:292-298.
46. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-1659.
47. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
48. Meneghini L, Wick A, Delamater A, et al. Group-based self-management intervention for intensification of insulin therapy [abstract]. Presented at: The 63rd Annual Scientific Sessions of the American Diabetes Association; June 13-17, 2003; New Orleans, La. Abstract 132-OR.
49. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care. 2003;26:799-804.
50. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1665-1671.
51. Novolog [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals Inc; 2004.
52. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583-588.
53. Apidra [package insert]. Kansas City, MO: sanofi-aventis; 2004.
54. Taylor R, Davies R, Fox C, Sampson M, Weaver JU, Wood L. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study.
55. Lantus [package insert]. Kansas City, MO: sanofi-aventis; 2003.